Japanese drugmaker Takeda has been awarded JPY24bn ($313m) to develop and a cell culture influenza vaccine and establish a commercial-scale production facility.
Catalent is to buy clinical trial supply assets from Aptuit for $410m (€285m) as it adds scale to handle the shift to preferred provider relationships.
in-PharmaTechnologist presents a roundup of recent ingredient and formulation research, including improved API impurity detection and a simple step to boost stability.
Repligen should consider selling its bioprocessing unit, which sells materials used in mAb production, to make best use of its assets, a shareholder suggests.
Encap Drug Delivery now offers a ‘feasibility package’ to assess the potential of its Phoral coating technology as a vehicle for therapy in colonic diseases.
Biosimilars should help Millipore achieve long-term growth but cancellation of an insulin contract and rising raw material costs hit second quarter results.
CMO Angel Biotechnologies has called in UK-based engineering group WH Partnership to help re-commissioning its GMP standard biomanufacturing facility in Cramlington near Newcastle-upon-Tyne.
Costly and time consuming drug screening could soon be a thing of the past thanks to new easy-bake synthetic cell membranes made at the Institute of Materials Research and Engineering (IMRE).
Scientists at the University of British Columbia have pioneered a magnetic retinal implant that can supply a regulated and on-demand release of drugs to treat blindness from diabetic retinopathy.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at INC Research, PPD, Catalent, Celerion, Pharmanet and CIToxLAB.
BioMarin will buy Pfizer’s biologics manufacturing plant in Shanbally, Cork, Ireland to add production capacity for its candidate mucopolysaccharidosis treatment.
Contract manufacturing organisation (CMO) Neuland Laboratories will showcase its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego, US later this week.
US stem-cell therapy firm NeoStem predicts that output of its China-based generic antibiotics subsidiary Suzhou Erye Pharmaceutical will increase after further manufacturing approval from the SFDA.
Sartorius Stedim Biotech (SSB) has teamed up with packaging firm Sudpack Medica AG in a deal focused on making plastic films for biopharmaceutical industry applications.
Switzerland-based life sciences supplier Lonza says it will invest CHF10m (€8m) to expand a Singapore plant that is part of its custom biomanufacturing business.
Irish pharma giant Elan is investing $20m (€14m) in US drug developer Proteostasis Therapeutics to speed the research and development of disease modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders.
PolyPid claims its new polymer-lipid combination delivery tech will let pharmas set precise release characteristics for a variety of small molecule, protein and nucleic acid-base drugs.
Florida-based contract manufacturing organisation (CMO), Goodwin Biotechnology (GBI), has entered into an agreement with protein and monoclonal antibody drug developer, Rafagen, to provide cell line engineering and biological contract manufacturing services.
Californian biotech tool manufacturer Life Technologies has teamed with German contract research organisation (CRO) ProBiogen to release a range of royalty-free Gibco Freedom Cell Line Development Kits.
Californian Bioreactor manufacturer, PBS Biotech, has launched its new PBS 3 single-use bioreactor system for the development of biological therapeutics, vaccines and biosimilars.
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.